Rapid Detection of HLA-B*57:01-Expressing Cells Using a Label-Free Interdigitated Electrode Biosensor Platform for Prevention of Abacavir Hypersensitivity in HIV Treatment.

Pre-treatment screening of individuals for human leukocyte antigens (HLA) HLA-B*57:01 is recommended for the prevention of life-threatening hypersensitivity reactions to abacavir, a drug widely prescribed for HIV treatment. However, the implementation of screening in clinical practice is hindered by the slow turnaround time and high cost of conventional HLA genotyping methods. We have developed a biosensor platform using interdigitated electrode (IDE) functionalized with a monoclonal antibody to detect cells expressing HLA-B*57:01. This platform was evaluated using cell lines and peripheral blood mononuclear cells expressing different HLA-B alleles. The functionalized IDE sensor was able to specifically capture HLA-B*57:01 cells, resulting in a significant change in the impedance magnitude in 20 min. This IDE platform has the potential to be further developed to enable point-of-care HLA-B*57:01 screening.

Vascular skin lesions in children: a review of laser surgical and medical treatments.

Vascular anomalies are a common finding in children. Although most of these lesions are benign, they can be a severe cosmetic problem and cause structural and functional damage to nearby tissues. As a result, physicians are tasked with developing effective treatment options with superior safety profiles. Vascular anomalies may be divided into tumors and malformations. Vascular tumors, such as infantile hemangiomas, typically appear a few months after birth, whereas the majority of vascular malformations, such as port-wine stains, are present at birth. Although these lesions vary in appearance, etiology, and disease course, many are treated in a similar fashion. In this review, we focus on treatment modalities for some of the more-prevalent childhood vascular lesions, including port-wine stains, primary telangiectasias, infantile hemangiomas, pyogenic granulomas, and angiomas.

Epidermodysplasia verruciformis associated with HPV 10.

Epidermodysplasia verruciformis (EV) is a rare, inherited dermatologic condition demonstrating an increased susceptibility to specific HPV genotypes, resulting in both benign and malignant skin lesions. Epidermodysplasia verruciformis lesions are frequently described as pityriasis versicolor-like scaly macules, flat wart-like papules, or verrucous and seborrhic keratosis-like papules and plaques. Acquired EV has been described in patients with HIV and in those who are on immunosuppressive therapy. We discuss a patient with congenital EV who presents with skin lesions associated with HPV 10, a less frequently cited causative subtype, and histological findings that are not classic for EV.

Evaluating anthracycline cardiotoxicity associated single nucleotide polymorphisms in a paediatric cohort with early onset cardiomyopathy.

BACKGROUND: Anthracyclines are a mainstay of chemotherapy. However, a relatively frequent adverse outcome of anthracycline treatment is cardiomyopathy. Multiple genetic studies have begun to dissect the complex genetics underlying cardiac sensitivity to the anthracycline drug class. A number of single nucleotide polymorphisms (SNPs) have been identified to be in linkage disequilibrium with anthracycline induced cardiotoxicity in paediatric populations. METHODS: Here we screened for the presence of SNPs resulting in a missense coding change in a cohort of children with early onset chemotherapy related cardiomyopathy. The SNP identity was evaluated by Sanger sequencing of PCR amplicons from genomic DNA of patients with anthracycline related cardiac dysfunction. RESULTS: All of the published SNPs were observed within our patient group. There was no correlation between the number of missense variants an individual carried with severity of disease. Furthermore, the time to cardiac disease onset post-treatment was not greater in those individuals carrying a high load of SNPs resulting from missense variants. CONCLUSIONS: We conclude that previously identified missense SNPs are present within a paediatric cohort with early onset heart damage induced by anthracyclines. However, these SNPs require further replication cohorts and functional validation before being deployed to assess anthracycline cardiotoxicity risk in the clinic.

Dating of divergences within the Rattus genus phylogeny using whole mitochondrial genomes.

The timing and order of divergences within the genus Rattus have, to date, been quite speculative. In order to address these important issues we sequenced six new whole mitochondrial genomes from wild-caught specimens from four species, Rattus exulans, Rattus praetor, Rattus rattus and Rattus tanezumi. The only rat whole mitochondrial genomes available previously were all from Rattus norvegicus specimens. Our phylogenetic and dating analyses place the deepest divergence within Rattus at approximately 3.5 million years ago (Mya). This divergence separates the New Guinean endemic R. praetor lineage from the Asian lineages. Within the Asian/Island Southeast Asian clade R. norvegicus diverged earliest at approximately 2.9Mya. R. exulans and the ancestor of the sister species R. rattus and R. tanezumi subsequently diverged at approximately 2.2Mya, with R. rattus and R. tanezumi separating as recently as approximately 0.4Mya. Our results give both a better resolved species divergence order and diversification dates within Rattus than previous studies.

Consumer demographics and expectations of probiotic therapy in New Zealand: results of a large telephone survey.

BACKGROUND: Knowledge regarding the possible health benefits of probiotic preparations has been increasing, but clinical trials have largely produced non-significant results. In contrast, the open market for probiotics is expanding worldwide despite little research of consumer characteristics. AIM: We aimed to survey the availability of probiotic preparations, the recommendation patterns of general practitioners (GP) and the characteristics of consumers. METHODS: Pharmacies were visited and the types of probiotic supplements were reviewed. A telephone survey was conducted to identify and characterise users and non-users. A questionnaire was sent to GPs. RESULTS: We found 31 probiotic products containing 16 different strains of bacteria. The majority of GPs were unable to clearly define a probiotic. Of 1512 random phone numbers called, 873 were answered. The prevalence of probiotic use was 25.4% of respondents. More females than males had ever used probiotics (30.6% vs 17.2%; p<0.0001). The highest rate of use was found in those with tertiary qualifications (34.2%; p<0.001). Of users, 75.2% said they had used probiotics on a recommendation, 80.5% of non-users said they would consider taking a probiotic if it was recommended by the GP. Probiotics were mainly used alongside antibiotic treatment (23%) and gastrointestinal disorders (27.5%). Significantly more users than non-users believed in the benefits of probiotic without concern for possible side effects. CONCLUSION: The majority of participants would consider taking a probiotic if it was recommended by their GP, but GPs exhibited a lack of knowledge in the use and indications for probiotic therapy. There was a general lack of concern regarding potential side-effects.

Controlled pilot study of the effects of neuromuscular therapy in patients with Parkinson's disease.

The objectives of this study is to examine the effects of neuromuscular therapy (NMT) on motor and nonmotor symptoms in Parkinson's disease (PD). Thirty-six subjects with PD were randomly assigned to NMT or music relaxation (MR, or active control). Subjects received treatment twice a week for 4 weeks. Testing was conducted at baseline, after final treatment, and 8 days after final treatment. Primary outcome measures were the Motor subscale of the United Parkinson Disease Rating Scale (UPDRS) and the Clinical Global Impression scale (CGI-Change). Secondary outcome measures included a PD-specific quality of life scale (PDQ-39), quantitative measures of motor function, and severity scales for anxiety and depression symptoms. NMT resulted in a significant and sustained improvement in the Motor subscale of the UPDRS (P < or = 0.0001), most notable in the tremor scores. Also improved 1 week after the last treatment were the CGI scores (P = 0.007) and the finger-tapping speed (P = 0.001). The MR active control group had a slight improvement in tremor but evidenced no other change in motor function. Both groups exhibited a modest improvement in quality of life immediately after the last treatment. This effect was sustained for 8 days only in the MR group. In the nonmotor domains, the MR group evidenced improvements in mood (P = 0.001) and anxiety (P = 0.002), whereas NMT had no effect on mood (P = 0.09), and its initial effect on anxiety (P = 0.0009) dissipated after 8 days (P = 0.40). Group differences for UPDRS motor score and patient CGI-Change were superior in the NMT compared to the MR group. There was no group difference in PDQ-39 scores or in nonmotor measures. The findings suggest that NMT can improve motor and selected nonmotor symptoms in PD and that this effect is more durable for the motor symptoms. The results of this pilot study warrant larger controlled studies to examine dose range, durability, and mechanisms of NMT in PD function.